XELOX (capecitabine plus oxaliplatin) as first-line treatment for elderly patients over 70 years of age with advanced colorectal cancer - Wikidata - wikimedia - TriplyDB

XELOX (capecitabine plus oxaliplatin) as first-line treatment for elderly patients over 70 years of age with advanced colorectal cancer

XELOX (capecitabine plus oxaliplatin) as first-line treatment for elderly patients over 70 years of age with advanced colorectal cancer

http://www.wikidata.org/entity/Q33370632

about

Can we predict toxicity and efficacy in older patients with cancer? Older patients with colorectal cancer as an example Efficacy, compliance and reasons for refusal of postoperative chemotherapy for elderly patients with colorectal cancer: a retrospective chart review and telephone patient questionnaire Decision-making in geriatric oncology: systemic treatment considerations for older adults with colon cancer.First-line bevacizumab and capecitabine-oxaliplatin in elderly patients with mCRC: GEMCAD phase II BECOX study.Capecitabine plus oxaliplatin compared with 5-fluorouracil plus oxaliplatin in metastatic colorectal cancer: Meta-analysis of randomized controlled trials.A phase II study of oxaliplatin, 5-fluorouracil, leucovorin, and high-dose capecitabine in patients with metastatic colorectal cancer.Treatment considerations in elderly colorectal cancer patients.Capecitabine and oxaliplatin combined with bevacizumab are feasible for treating selected Japanese patients at least 75 years of age with metastatic colorectal cancer.First-line cetuximab plus capecitabine in elderly patients with advanced colorectal cancer: clinical outcome and subgroup analysis according to KRAS status from a Spanish TTD Group Study.Grade 3/4 neutropenia is a limiting factor in second-line FOLFIRI following FOLFOX4 failure in elderly patients with metastatic colorectal cancer Chemotherapy for Late-Stage Cancer Patients: Meta-Analysis of Complete Response Rates.A review of the role of capecitabine in the treatment of colorectal cancer.Colorectal cancer treatment in older patients.Colorectal cancer treatment in the elderly: tailored therapy approaches Colon cancer and the elderly: from screening to treatment in management of GI disease in the elderly.Role of chemotherapy and novel biological agents in the treatment of elderly patients with colorectal cancer.Role of oxaliplatin in the treatment of colorectal cancer Oxaliplatin-based chemotherapy in the management of colorectal cancer.Adjuvant therapy for rectal cancer Challenges in the management of older patients with colon cancer Role of cetuximab in first-line treatment of metastatic colorectal cancer XELOX in colorectal cancer: a convenient option for the future?A retrospective cohort study of metastatic colorectal cancer patients treated with oxaliplatin-based chemotherapy, with an exploratory analysis of changing serum carcinoembryonic antigen levels.Metastatic colorectal cancer in the elderly: An overview of the systemic treatment modalities (Review).Should capecitabine replace 5-fluorouracil in the first-line treatment of metastatic colorectal cancer?Phase I/II trial of dose-reduced capecitabine in elderly patients with advanced colorectal cancer.Oxaliplatin-induced lung fibrosis.Phase II trial of S-1 monotherapy in elderly or frail patients with metastatic colorectal cancer.

P2860

Q28069620-EADA2C93-0FDE-4732-B21B-27DFA7B55ABD Q28486580-F52AD979-EA52-47E3-8AE4-742A782988FE Q30244769-BCA4BF86-6103-42CF-88B7-050D73AD89A7 Q33918152-50A485CD-DAE9-4C69-B413-065223C8FAC8 Q34639725-6177482F-780F-41C4-998A-0D4AB68BBA26 Q34682635-66369F8A-AE42-4573-B7CA-5CF7E0820FCE Q35234803-5B24BBCE-905C-463A-8C19-85D67801E11D Q35819857-01EBD328-4A1D-4A21-8569-D2BD7A8BF85C Q35863869-32554BEE-41A0-4D4E-A5B7-791DE0811132 Q36135372-3AA5406B-0478-45D5-9BF9-A0CFF533F880 Q36444444-946C3512-913C-41DF-BBB4-120245874C38 Q36661290-5B968FA1-086A-45D9-B44C-928BB3CBD614 Q37073448-193007A1-787E-4186-8031-90A93E124297 Q37073451-EC9017CB-E997-46B5-8831-19D7F71A8E79 Q37092129-636673BE-96BF-4160-B2FB-76184A28A4E0 Q37113563-95B018FF-7D71-47AC-9A7D-942D27BD48C9 Q37230238-BC3635C4-C462-43A5-AC36-93F1802B5EDD Q37242664-E2C2E21B-123D-458E-9D98-6FE02DFD1B1F Q37462241-DD76E5E3-14A5-45D6-8AE1-718C6B695D29 Q37598467-AA71C602-C30C-443C-A0D3-03578A9A8D22 Q37708010-EA595F4C-D24A-4E1B-9C90-6733D52F41E7 Q37839084-B7847E26-A78E-4B20-AAB2-D826D7E25C71 Q38004607-6BD1B977-DC30-4400-84D3-B8813A824051 Q38032558-7485ED9A-1E4E-4565-AB96-665202B5683D Q38216008-C1C2179E-3AC5-4F20-B4E1-B08DBD602602 Q41559464-F1911642-5583-4042-9982-5D60ABBED4EE Q42445751-A278A88A-3359-48F9-8CC1-7D8DF4BA20BF Q53476543-4B39E569-5351-48CB-B9F5-81DA61E81A18

P2860

XELOX (capecitabine plus oxaliplatin) as first-line treatment for elderly patients over 70 years of age with advanced colorectal cancer

http://www.wikidata.org/entity/Q33370632

description

2006 nî lūn-bûn

@nan

2006 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2006 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2006年の論文

@ja

2006年論文

@yue

2006年論文

@zh-hant

2006年論文

@zh-hk

2006年論文

@zh-mo

2006年論文

@zh-tw

2006年论文

@wuu

name

XELOX (capecitabine plus oxali ...... ith advanced colorectal cancer

@ast

XELOX (capecitabine plus oxali ...... ith advanced colorectal cancer

@en

type

label

XELOX (capecitabine plus oxali ...... ith advanced colorectal cancer

@ast

XELOX (capecitabine plus oxali ...... ith advanced colorectal cancer

@en

prefLabel

XELOX (capecitabine plus oxali ...... ith advanced colorectal cancer

@ast

XELOX (capecitabine plus oxali ...... ith advanced colorectal cancer

@en

P1433

Q33370632-C1FDBC72-1CB0-49E3-9147-9DE02F74C8B4

P1476

Q33370632-D42DD0BA-EBB8-4F60-B0B1-2FD9CE32561F

P2093

Q33370632-011D48F0-40FB-4952-B0F9-04CC58A6D836

Q33370632-163C50AD-A41E-4BEF-995F-5DBFE628EE5D

Q33370632-26B6CC5A-F4C3-4EED-A99B-F68E8626E783

Q33370632-620302D4-CAD1-404D-B9E3-C8EE08013976

Q33370632-7809A50B-B0E7-4A1D-B4B2-D9D232806DD8

Q33370632-89454471-18E1-4EC8-8BBE-DBB0621B8D61

Q33370632-A157D698-5A4B-424D-ACC3-B3DF9D8A5294

Q33370632-BD316BE0-FFD0-4015-A478-753E2D1FE710

Q33370632-BDF5F6C8-08E4-457F-9E70-7F8C1C5B15CC

Q33370632-CC7A4160-5929-40D7-B0A1-DF942C9F9FD0

P2860

Q33370632-021CD988-5F54-4D24-AAFC-9765F78542DB

Q33370632-06790D9D-20F6-4B95-9978-8CE26DA8E4CE

Q33370632-07EC9105-9828-431C-88D0-59DAEBA99AD8

Q33370632-0E2BAFB2-7074-4629-9ADF-C13D4702D96F

Q33370632-10FEF7E0-9639-4FDA-967B-A16B828242FE

Q33370632-19D744F7-5E95-44FE-8CFB-9F581DD3AB50

Q33370632-278CB64B-66B8-4F6F-B16F-1E1AF2D7DC29

Q33370632-291BF640-DC08-4EB6-BCD4-76087013EC7F

Q33370632-298FC84C-38C1-46AA-A8F6-3BA8800749F5

Q33370632-2C997A2F-184D-4E54-B447-830ADED4427B

P2888

Q33370632-1E1C3239-F6B5-42A9-AF3D-E81586D89633

P304

Q33370632-612DA8A0-1355-46E4-88BD-C8F184B878C8

P31

Q33370632-34C13A58-E69E-45D7-889D-B8D2AC3C9F6B

P356

Q33370632-86D01FB7-5980-4D27-B76D-E4565E68A2B8

P407

Q33370632-1EB7DBDE-9984-45C2-A810-0D254E3B4DEE

P433

Q33370632-C7C20F1B-7ED2-44DE-9438-6BA1210AD202

P478

Q33370632-8C8F1432-7970-49F2-8F6B-6469527C5350

P50

Q33370632-14435AA6-16D9-4CC9-BDFA-0A1B0CE3F034

P577

Q33370632-385F087B-7D0B-4A6D-ABAA-2FB38401FD25

P5875

Q33370632-6E0676E4-F562-4770-81D0-27D4DACFC4F5

P6179

Q33370632-ABE94ED6-259E-4895-B4F7-A3572027F672

P698

Q33370632-8B931658-9B38-4995-9418-A5A7CB7EDC9B

P921

Q33370632-76B9AFC7-FD88-4BDC-BE6D-569408D9299A

P932

Q33370632-9FCFBE6A-B1BA-48A3-BB4A-B06156451E53

P356

P1433

British Journal of Cancer

P1476

XELOX (capecitabine plus oxali ...... ith advanced colorectal cancer

@en

P2093

A Galán

http://www.w3.org/2001/XMLSchema#string

A Yubero

http://www.w3.org/2001/XMLSchema#string

E Casado

http://www.w3.org/2001/XMLSchema#string

F Losa

http://www.w3.org/2001/XMLSchema#string

J De Castro

http://www.w3.org/2001/XMLSchema#string

J Feliu

http://www.w3.org/2001/XMLSchema#string

J-M Vicent

http://www.w3.org/2001/XMLSchema#string

L Lopez-Gómez

http://www.w3.org/2001/XMLSchema#string

M A de Mon

http://www.w3.org/2001/XMLSchema#string

M Bolaños

http://www.w3.org/2001/XMLSchema#string

P2860

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue.

Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial

FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study

A new method of classifying prognostic comorbidity in longitudinal studies: development and validation

Prediction of creatinine clearance from serum creatinine

Capecitabine as first-line treatment for patients older than 70 years with metastatic colorectal cancer: an oncopaz cooperative group study.

Upper extremity deep vein thrombosis.

Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer.

Should chemotherapy be used as a treatment of advanced colorectal carcinoma (ACC) in patients over 70 years of age?

P2888

P304

969-975

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/SJ.BJC.6603047

http://www.w3.org/2001/XMLSchema#string

P407

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

94

http://www.w3.org/2001/XMLSchema#string

P50

P577

2006-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

46847513

http://www.w3.org/2001/XMLSchema#string

P6179

1039585820

http://www.w3.org/2001/XMLSchema#string

P698

16552438

http://www.w3.org/2001/XMLSchema#string

P921

colorectal cancer

P932

2361238

http://www.w3.org/2001/XMLSchema#string